Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Polio is a highly infectious disease caused by a virus. It invades the nervous system, and can cause total paralysis in a matter of hours. The virus enters the body through the mouth and multiplies in the intestine. Initial symptoms are fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. One in 200 infections leads to irreversible paralysis (usually in the legs). Among those paralysed, 5% to 10% die when their breathing muscles become immobilized. There is no cure for polio, it can only be prevented. Polio vaccine, given multiple times, can protect a child for life.
Compare in newborns the immunogenicity and safety of the vaccine OPV produced by Birmex compared with the vaccine OPV produced by Sanofi Pasteur, both produced in Vero cells.
This is a randomized clinical trial, which includes 320 newborns of both sexes and residents of the state of México, 160 newborns receive the vaccine OPV Birmex and 160 newborns receive the vaccine OPV Sanofi Pasteur
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Trivalent OPV Birmex | Experimental | Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application. |
|
| Trivalent OPV Sanofi Pasteur | Active Comparator | Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trivalent OPV Birmex | Biological | Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application. |
| Measure | Description | Time Frame |
|---|---|---|
| Change seroconversion after one dose of trivalent vaccine OPV | after the first dose is taken blood samples (baseline, 30 and 60 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the adverse events in newborns babies | inmediately after treatment and during 60 days |
| Measure | Description | Time Frame |
|---|---|---|
| Poliovirus Excretion | Evaluate viral excretion rate, basal 7, 14, 21 and 28 days after vaccination of two vaccines against polio OPV in newborns Mexicans |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alvaro García-Pérez, MD | Contact | 5554222840 | 139 | agarciap@birmex.gob.mx |
| Name | Affiliation | Role |
|---|---|---|
| Mauricio Rodríguez Álvarez, PhD | Laboratorios de Biológicos y Reactivos de México S.A de C.V | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital General de Chalco Dr. Fernando Quiroz Gutierrez | Recruiting | Valle de Chalco | State of Mexico | 56613 | Mexico |
Not provided
| Label | URL |
|---|---|
| Laboratorios de Biológicos y Reactivos de México S.A de C.V | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D011051 | Poliomyelitis |
| ID | Term |
|---|---|
| D009187 | Myelitis |
| D002494 | Central Nervous System Infections |
| D007239 | Infections |
| D004769 | Enterovirus Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Trivalent OPV Sanofi Pasteur | Biological | Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application. |
|
|
| D010850 |
| Picornaviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D013118 | Spinal Cord Diseases |
| D000090862 | Neuroinflammatory Diseases |
| D009468 | Neuromuscular Diseases |